Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Open-label, Nonrandomized Study of FGFR Inhibitor Futibatinib in Combination With MEK-inhibitor Binimetinib in Patients With Advanced KRAS Mutant Cancer

NCT04965818 is registered in ClinicalTrials.gov with Taiho Oncology, Inc. as lead sponsor.

NCT NCT04965818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04965818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Open-label, Nonrandomized Study of FGFR Inhibitor Futibatinib in Combination With MEK-inhibitor Binimetinib in Patients With Advanced KRAS Mutant Cancer
Lead sponsor
Taiho Oncology, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
September 20, 2021
Completion date
September 21, 2023
Enrollment
38 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors irrespective of gene alterations, kras gene mutation, non-small cell lung cancer